Ground breaking new procedures in Europe for assessing the relative effectiveness of new drugs at an EU-level are due to go live from January 2025 and companies must be ready.
Navigating The Uncharted Waters Of EU HTA
The EU-level joint clinical assessments that will be introduced under the Health Technology Assessment Regulation from January 2025 represent a huge shift for drug companies launching products in the EU. Industry experts Alexander Natz and Matias Olsen offer key advice to help companies prepare for what is to come.
